Hollencrest Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hollencrest Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.95K	Hold	16	–	–	﹤0.01%	852
2026 Q1	$7.14K	Hold	16	–	–	﹤0.01%	876
2025 Q4	$7.25K	Hold	16	–	–	﹤0.01%	861
2025 Q3	$6.27K	Hold	16	–	–	﹤0.01%	870
2025 Q2	$7.12K	Hold	16	–	–	﹤0.01%	823
2025 Q1	$7.76K	Sell	16 -179	-92%	-$83.4K	﹤0.01%	810
2024 Q4	$78.5K	Sell	195 -100	-34%	-$46.4K	﹤0.01%	454
2024 Q3	$137K	Hold	295	–	–	0.01%	335
2024 Q2	$138K	Buy	295 +100	+51%	+$43.4K	0.01%	335
2024 Q1	$81.5K	Sell	195 -957	-83%	-$405K	﹤0.01%	398
2023 Q4	$469K	Buy	1,152 +179	+18%	+$66.1K	0.04%	201
2023 Q3	$338K	Hold	973	–	–	0.04%	215
2023 Q2	$342K	Hold	973	–	–	0.04%	223
2023 Q1	$307K	Buy	973 +957	+5,981%	+$287K	0.03%	228
2022 Q4	$4.62K	Buy	+16	New	+$4.88K	﹤0.01%	840

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hollencrest Capital Management's VRTX Position: Q2 2026 in Review

Hollencrest Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 16 shares worth $7.95K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Hollencrest Capital Management first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $469K in Q4 2023. 1,753 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Hollencrest Capital Management held 16 shares of Vertex Pharmaceuticals worth $7.95K as of Q2 2026.
Hollencrest Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #852 holding.
Hollencrest Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
Hollencrest Capital Management's Vertex Pharmaceuticals position peaked at $469K in Q4 2023.
1,753 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.